Phase 2 Prostate cancer trials recruiting now

All Prostate cancer trials, every phase

Other phases for Prostate cancer

Phase 2 Prostate cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
  NCT06449781 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
  NCT05155046 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: Male · 1 location
• 2 Ablative RadioTherapy Treatments for Prostate Cancer
  NCT04654338 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: Male · 1 location
• 4-aminopyridine Treatment for Nerve Injury
  NCT03701581 · Phase: Phase 2, Phase 3 · Ages: 45 Years to 75 Years · Sex: Male · 2 locations
• 64Cu-GRIP B in Patients With Advanced Malignancies
  NCT05888532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
  NCT04868604 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
  NCT07209878 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
  NCT07332000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 82 locations
• A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
  NCT07198633 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
  NCT07407283 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 85 Years · Sex: Male · 2 locations
• A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
  NCT07689656 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
  NCT07250542 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
  NCT07258407 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
  NCT07255664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
  NCT06970119 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
  NCT07292168 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
  NCT06785636 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 54 locations
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
  NCT04633252 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 110 Years · Sex: Male · 1 location
• A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
  NCT05361798 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
  NCT06241846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 24 locations
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
  NCT06085664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
  NCT03258320 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 75 Years · Sex: Male · 2 locations
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
  NCT05593497 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
  NCT06906471 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 2 locations
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
  NCT07567846 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 5 locations
• A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
  NCT06689163 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
  NCT06347705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
  NCT07730021 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
  NCT07335796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• A Study of DM002 in Patients With Advanced Solid Tumors
  NCT06751329 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
  NCT05726292 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
  NCT06782555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06842498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
  NCT06990880 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 90 locations
• A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
  NCT06568094 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 2 locations
• A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
  NCT07635238 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study of MHB048C in Patients With Advanced Solid Tumors
  NCT07192120 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
  NCT07230106 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 2 locations
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT06533644 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
  NCT07567521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
  NCT06844383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 8 locations
• A Study of Tarlatamab for People With Prostate Cancer
  NCT07111507 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 10 locations
• A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
  NCT07259213 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
  NCT06457919 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 12 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
  NCT05751434 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 10 locations
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
  NCT06155084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 27 locations
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
  NCT06609005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
  NCT07192614 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 26 locations
• A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
  NCT07450599 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 23 locations
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07287150 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 48 locations
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
  NCT07336446 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 18 locations
• AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
  NCT07285694 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
  NCT07414940 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
  NCT06397703 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
  NCT05113537 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
  NCT07237269 · Phase: Phase 2 · Ages: 30 Years and older · Sex: Male · 1 location
• Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
  NCT06173362 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
  NCT05422911 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 12 locations
• Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
  NCT05915442 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: Male · 1 location
• Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
  NCT07711314 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
  NCT05454488 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
  NCT06865768 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
  NCT07185165 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 1 location
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
  NCT07206056 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 35 locations
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
  NCT04947254 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
  NCT07025369 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Androgen-responsive POSLUMA-guided Intra-prostatic Boost
  NCT07393867 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 4 locations
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
  NCT05413850 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 21 locations
• Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
  NCT05761366 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
  NCT06772441 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
  NCT06582446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
  NCT07455903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
  NCT05969860 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Axelopran for Advanced Cancer in Patients Receiving Opioids
  NCT07354919 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
  NCT06237179 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 85 Years · Sex: Male · 2 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
  NCT07523529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT04704505 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Bipolar Androgen Therapy + Carboplatin in mCRPC
  NCT03522064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
  NCT05869682 · Phase: Phase 2 · Ages: 60 Years and older · Sex: Male · 1 location
• COAST Therapy in Advanced Solid Tumors and Prostate Cancer
  NCT05036226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
  NCT06738303 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT05168618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Cannabidiol for Pain Relief of Patients With End-stage mCRPC
  NCT07549256 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 133 locations

Showing 100 of 344 recruiting trials.

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.